Proportional correlates of adipolin and cathepsin S in metabolic syndrome patients with and without prediabetes.

Background: Adipolin and cathepsin S are intricately involved in pathophysiology of metabolic syndrome (MetS) and prediabetes (PreDM).

Aims & Methods: This cross-sectional study aimed to compare and correlate between these metabolic biomarkers as well as between them and adiposity, atherogenicity and hematological indices in MetS patients. Our cross-sectional study involved recruiting 29 normoglycemic MetS, 30 newly diagnosed drug naïve PreDM-MetS patients versus 29 lean, healthy and normoglycemic controls.

Increased irisin versus reduced fibroblast growth factor1 (FGF1) in relation to adiposity, atherogenicity and hematological indices in metabolic syndrome patients with and without prediabetes.

Background Irisin and fibroblast growth factor 1 (FGF1) are intricately involved in metabolic syndrome (MetS) and prediabetes (preDM) pathophysiology. This study aimed to compare and correlate irisin and FGF1 plasma levels, adiposity, atherogenicity and hematological indices in 29 normoglycemic MetS and 30 newly diagnosed drug naive prediabetic (PreDM) MetS patients vs. 29 lean and normoglycemic controls.

Cross-sectional correlates of nesfatin and lipopolysaccharide binding protein in metabolic syndrome patients with and without prediabetes.

Background Metabolic syndrome (MetS) and prediabetes (preDM) have crosslinked pathophysiologies with central obesity and insulin resistance (IR). This study aimed to compare and correlate nesfatin and lipopolysaccharide binding protein (LBP) plasma levels, adiposity, atherogenicity and hematological indices between non-diabetic MetS, newly diagnosed drug naive pre-diabetic MetS patients vs. normoglycemic lean controls.